Equillium announces data from phase 1b equalise study presented at the 2023 annual meeting of the american society of nephrology

La jolla, calif.--(business wire)---- $eq #gvhd--equillium, inc. (nasdaq: eq), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced that data from the type b portion of the equalise study in lupus nephritis patients was presented at the annual meeting of the american society of nephrology (asn). the data highlights that subjects had high complete and partial response rates with rapid and deep reduction in urine.
EQ Ratings Summary
EQ Quant Ranking